Neuronetics, Inc. (NASDAQ:STIM) Short Interest Update

Neuronetics, Inc. (NASDAQ:STIM) was the target of a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 312,900 shares, a decline of 35.8% from the December 15th total of 487,400 shares. Approximately 2.0% of the shares of the company are short sold. Based on an average daily trading volume, of 413,300 shares, the short-interest ratio is currently 0.8 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Gabelli Funds LLC lifted its holdings in Neuronetics by 88.2% in the second quarter. Gabelli Funds LLC now owns 48,000 shares of the company’s stock worth $86,000 after purchasing an additional 22,500 shares during the period. GSA Capital Partners LLP lifted its stake in shares of Neuronetics by 64.5% in the 3rd quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock worth $60,000 after acquiring an additional 30,837 shares during the period. Acadian Asset Management LLC boosted its holdings in shares of Neuronetics by 23.7% in the second quarter. Acadian Asset Management LLC now owns 326,975 shares of the company’s stock valued at $587,000 after acquiring an additional 62,628 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new position in shares of Neuronetics during the third quarter valued at approximately $53,000. Finally, HighTower Advisors LLC raised its holdings in Neuronetics by 55.5% during the third quarter. HighTower Advisors LLC now owns 245,982 shares of the company’s stock worth $187,000 after purchasing an additional 87,816 shares in the last quarter. Institutional investors own 53.59% of the company’s stock.

Neuronetics Stock Up 36.8 %

STIM opened at $2.34 on Tuesday. The stock’s 50 day moving average price is $1.18 and its 200 day moving average price is $1.21. The company has a debt-to-equity ratio of 4.90, a current ratio of 3.16 and a quick ratio of 2.87. The stock has a market cap of $71.01 million, a P/E ratio of -1.90 and a beta of 2.11. Neuronetics has a 12 month low of $0.52 and a 12 month high of $5.07.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.